Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

Inclusion Criteria: * Patients must have histologically or cytologically documented newly diagnosed de novo Acute Myeloid Leukemia (non-APL) that has not yet been treated. Hydrea,cytarabine and ATRA previous treatments are acceptable. * Patients with core binding factor acute myeloid leukemia (AML) (ie AML with t(8;21) or t(16;16) or i16) are not eligible. * Patients must not have a secondary AML (defined as a history of prior radiation therapy or systemic chemotherapy, CMML or MDS not treated with a hypomethylating agent) however history of previous MDS treated with a hypomethylating agent IS allowed. * Patients with de novo AML must not have partial or total monosomy 5 or 7 or i(17q) or t(17p). Negative FISH studies are sufficient for enrollment (i.e. FISH for -5, -7, +8, inv(16), t(8;21) and 17p). * Patients must not have mutated FLT3 (either ITD OR TKD mutations). * Hydroxyurea, leukapheresis or cytarabine may be used to control leukocytosis, provided that it is without Grade \>2 non-hematologic toxicity, and can be taken until start of therapy. * Age \>18 years. * ECOG performance status of ≤ 2 and fit for induction therapy in the opinion of the treating physician. * Laboratory values ≤2 weeks must be: * AST(SGOT)/ALT(SGPT)≤ 2.5 X institutional upper limit of normal * Bilirubin ≤ 2 X ULN (3X if known history of Gilbert'syndrome) * Creatinine clearance (CrCl) must be \> 20 mL/min * Baseline left ventricular ejection fraction of at least 40% by MUGA or ECHO. * Female pati…